If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insurance Group Regulatory News (SBRE)

Share Price Information for Sabre Insurance Group (SBRE)

Share Price is delayed by 15 minutes
Get Live Data
183.60    2.60 (1.44%)
Bid:
182.40
Ask:
183.00
Spread: 0.60 (0.329%)
Market Cap: £446.53m
SBRE Live PriceLast checked at - London Stock Exchange

Intraday Sabre Insurance Group Share Chart

Trading Update

10 Oct 2019 07:00

RNS Number : 3561P
Sabre Insurance Group PLC
10 October 2019
 

10 October 2019

 

SABRE INSURANCE GROUP PLC

Trading Update

Sabre Insurance Group plc (the "Group", or "Sabre"), one of the UK's leading private motor insurance underwriters, today provides a trading update for the nine months ending 30 September 2019.

Summary

·; The Group continues to execute its strategy of focusing on underwriting profitability over premium growth in order to maximise profitability over the long term.

·; The Group anticipates delivering a FY2019 combined ratio slightly better than our mid 70%'s target (FY2018: 70.6%).

·; As anticipated, gross written premiums (GWP) for the first nine months of the year are lower year-on-year at £152.9m(1) (2018: £162.6m). The Group expects full year GWP to be approximately 7% lower than 2018 (FY2018: £210.0m), in line with previous guidance.

·; Disciplined underwriting and well controlled claims management have successfully mitigated the anticipated ongoing increase in claims inflation and other cost pressures.

·; Strong organic capital generation supports the potential for an attractive full year dividend with a solvency coverage ratio of 198%(1) as at the end of September 2019 (2018: 195%), above our 140% to 160% target range.

 

Geoff Carter, Chief Executive Officer, commented:

Throughout a period of significant change in the UK motor insurance sector, we have continued to apply our long-term strategy, to focus on underwriting profitability, with premium volume remaining an output rather than a target.

We continue to observe high levels of industry-wide claims inflation, and are additionally focused on other emerging cost pressures. These include increases in the MIB and FSCS levies, potential reinsurance price rises following the Ogden rate decision and possible changes in claims management company behaviour following the implementation of the forthcoming personal injury legal reforms.

Encouragingly, early signs of market premium increases or other competitor actions mean that while we have accelerated price increases to cover these emerging costs as well as ongoing inflation, our volumes are not being further negatively impacted.

We note the recent FCA report on pricing in the insurance industry. Given Sabre's approach is to price policies on a consistent basis across our new and renewal portfolios we do not anticipate that the proposed remedies will have a detrimental impact on our business.

Our performance so far in this financial year has been in line with our expectations and we remain confident that we will deliver a combined ratio slightly below our long-term target and an attractive dividend for the full year, supported by our current solvency ratio of 198%, which is well above our target 140% to 160% range.

(1) Numerical information not subject to audit

 

 

Investor enquiries

Sabre Insurance Group plc

Adam Westwood, Chief Financial Officer

adam.westwood@sabre.co.uk

01306 747 272

Media enquiries

Tulchan Communications LLP

James Macey White and Amber Ahluwalia

020 7353 4200

sabre@tulchangroup.com

 

 

LEI code: 2138006RXRQ8P8VKGV98

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTLLFEEITLAIIA
Date   Source Headline
16th Jul 20257:00 amRNSTransaction in Own Shares
15th Jul 20257:00 amRNSTransaction in Own Shares
14th Jul 20257:00 amRNSTransaction in Own Shares
11th Jul 202510:55 amRNSDirector/PDMR Shareholding
11th Jul 20257:00 amRNSTransaction in Own Shares
10th Jul 20257:00 amRNSTransaction in Own Shares
9th Jul 20257:00 amRNSTransaction in Own Shares
8th Jul 20257:00 amRNSTransaction in Own Shares
7th Jul 20257:00 amRNSTransaction in Own Shares
4th Jul 20257:00 amRNSTransaction in Own Shares
3rd Jul 20257:00 amRNSTransaction in Own Shares
2nd Jul 20257:00 amRNSTransaction in Own Shares
1st Jul 20257:00 amRNSTransaction in Own Shares
17th Jun 20254:35 pmRNSDirector/PDMR Shareholding
11th Jun 20251:38 pmRNSDirector/PDMR Shareholding
5th Jun 202511:16 amRNSDirector/PDMR Shareholding
22nd May 202511:38 amRNSResult of AGM
22nd May 20257:00 amRNSTrading Update
13th May 20253:18 pmRNSDirector/PDMR Shareholding
17th Apr 20259:40 amRNSDirector/PDMR Shareholding
11th Apr 20251:26 pmRNSDirector/PDMR Shareholding
10th Apr 20251:09 pmRNSDirector/PDMR Shareholding
8th Apr 20254:31 pmRNSDirector/PDMR Shareholding
8th Apr 20253:54 pmRNSDirector/PDMR Shareholding
8th Apr 20251:53 pmRNSDirector/PDMR Shareholding
4th Apr 20253:20 pmRNSNotice of AGM
27th Mar 20258:37 amRNSDirector/PDMR Shareholding
20th Mar 202511:39 amRNSDirector/PDMR Shareholding
18th Mar 20257:00 amRNSFinal Results
11th Mar 20251:21 pmRNSDirector/PDMR Shareholding
24th Feb 202511:23 amRNSNotice of Results
11th Feb 20253:12 pmRNSDirector/PDMR Shareholding
13th Jan 20252:14 pmRNSDirector/PDMR Shareholding
11th Dec 202411:57 amRNSDirector/PDMR Shareholding
5th Dec 20247:00 amRNSCapital Markets Event
21st Nov 202410:28 amRNSAppointment of Joint Corporate Broker
12th Nov 20241:15 pmRNSDirector/PDMR Shareholding
23rd Oct 20244:13 pmRNSHolding(s) in Company
22nd Oct 20242:43 pmRNSDirector/PDMR Shareholding
22nd Oct 20242:40 pmRNSDirector/PDMR Shareholding
22nd Oct 20247:00 amRNSTrading Update
18th Oct 20243:25 pmRNSHolding(s) in Company
11th Oct 202412:40 pmRNSDirector/PDMR Shareholding
26th Sep 20241:25 pmRNSDirector/PDMR Shareholding
11th Sep 202412:21 pmRNSDirector/PDMR Shareholding
11th Sep 20249:51 amRNSHolding(s) in Company
6th Sep 20242:29 pmRNSHolding(s) in Company
30th Aug 202411:50 amRNSDirector/PDMR Shareholding
22nd Aug 20244:22 pmRNSHolding(s) in Company
14th Aug 20243:33 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.